Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

Yueming Tang, Adam Braun, Zachary von Behren, Jieya Wu, Caitlyn Haley, Chunxiao Zhang, Brenda Loera, Pina M. Cardarelli, Nina Caculitan, Sylvia Chien, Jin Dai, Vivian G. Oehler, Jianying Zhang, Guido Marcucci, Pamela S. Becker

Blood (2024) 144 (Supplement 1): 2758.

https://doi.org/10.1182/blood-2024-210120

Published: 2024

Journal Articles

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Piyanuch Kongtim, Mary-Elizabeth M. Percival, Timothy J Martins, Guangrong Qin, Niall Curley, Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker

Blood (2022) 140 (Supplement 1): 1200–1202.

https://doi.org/10.1182/blood-2022-165801

Published: 2022

Journal Articles

Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors

Vivian G. Oehler, Sylvia Chien, Jin Dai, Carrie L. Cummings, James Annis, Timothy J Martins, Pamela S. Becker

Blood (2021) 138 (Supplement 1): 268.

https://doi.org/10.1182/blood-2021-151933

Published: 2021

Journal Articles

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Guangrong Qin, PhD, Shmulevich Ilya, PhD, Taek-Kyun Kim, PhD, Bahar Tercan, PhD, Timothy J Martins, PhD, Jin Dai, PhD, Sylvia Chien, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD, Lawrence A. Loeb, MD PhD, Raymond J. Monnat, MD PhD, Pamela S. Becker, MDPhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142727

Published: 2020

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

Blood (2017) 130 (Supplement 1): 4622.

https://doi.org/10.1182/blood.V130.Suppl_1.4622.4622

Published: 2017

Journal Articles

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2016) 128 (22): 4043.

https://doi.org/10.1182/blood.V128.22.4043.4043

Published: 2016

Journal Articles

Precision Medicine Assays Detect Novel Targetable FLT3 Fusions Amenable to Therapeutic Intervention in a Patient with Refractory Acute Myeloid Leukemia

Bradley A Patay, MD, Andrew Carson, PhD, Timothy J Martins, PhD, Sylvia Chien, Mary-Elizabeth M. Percival, MD MS, Taylor Sekizaki, Cody Hammer, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5170.

https://doi.org/10.1182/blood.V128.22.5170.5170

Published: 2016

Journal Articles

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Joe C Huang, MD, Yifan Lu, B.S., Julia Sidorova, PhD, Sylvia Chien, Vivian Oehler, MD, Kenneth J Kopecky, PhD, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5063.

https://doi.org/10.1182/blood.V128.22.5063.5063

Published: 2016

Journal Articles

Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage

Joe Chin-Sun Huang, MD, Julia Sidorova, PhD, Sylvia Chien, Jin Dai, Ben Logsdon, PhD, Su-In Lee, PhD, Raymond J Monnat, MD, Pamela S. Becker, MD PhD

Blood (2015) 126 (23): 3629.

https://doi.org/10.1182/blood.V126.23.3629.3629

Published: 2015

Journal Articles

Feasibility Trial of Individualized Therapy for Relapsed or Refractory Acute Myeloid Leukemia Based on a High Throughput in Vitro Drug Sensitivity Assay

Pamela S. Becker, MD PhD, Vivian Oehler, MD, Elihu H. Estey, MD, Timothy Martins, PhD, Andrea Perdue, PA-C, Jodie David, RN, Sylvia Chien, Paul C. Hendrie, MD PhD, Fabiana Ostronoff, MD, C. Anthony Blau, MD

Blood (2014) 124 (21): 3748.

https://doi.org/10.1182/blood.V124.21.3748.3748

Published: 2014

Journal Articles

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sylvia Chien, Lauren E. Beyerle, Brent L. Wood, MD, PhD, Elihu H. Estey, MD, Frederick R. Appelbaum, MD, Pina M. Cardarelli, Ph.D., Peter Sabbatini, PhD, Suresh Shelat, MD-PhD, Lewis Cohen, MD, MS, Pamela S. Becker, MD, PhD

Blood (2013) 122 (21): 3882.

https://doi.org/10.1182/blood.V122.21.3882.3882

Published: 2013

Journal Articles

Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay

Ka Yee Yeung, Ph.D., C. Anthony Blau, MD, Vivian G. Oehler, MD, Su-In Lee, Ph.D., Christopher P. Miller, PhD, Sylvia Chien, Timothy Martins, PhD, Elihu H. Estey, MD, Pamela S. Becker, MD, PhD

Blood (2013) 122 (21): 483.

https://doi.org/10.1182/blood.V122.21.483.483

Published: 2013

Journal Articles

Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation

Sylvia Chien, Siraj U. Haq, Matthew Pawlus, Ph.D., Randall T. Moon, Ph.D., Elihu H. Estey, M.D., Frederick R. Appelbaum, MD, Megan Othus, PhD, John L. Magnani, PhD, Pamela S. Becker, MD, PhD

Blood (2013) 122 (21): 61.

https://doi.org/10.1182/blood.V122.21.61.61

Published: 2013

Journal Articles

A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2Rgc −/− Mice Engrafted with Human AML

Sylvia Chien, Xin Zhao, MD, Margaret Brown, Akanksha Saxena, BS, John T. Patton, PhD, John L. Magnani, PhD, Pamela S Becker, MD, PhD

Blood (2012) 120 (21): 4092.

https://doi.org/10.1182/blood.V120.21.4092.4092

Published: 2012

Journal Articles

Characterization of Mesenchymal Stromal Cells (MSCs) Derived From Acute Myeloid Leukemia (AML) Bone Marrow

Soumit K. Basu, MD, PhD, Xin Zhao, MD, Sylvia Chien, Min Fang, MD, PhD, Vivian Oehler, MD, Pamela S Becker, MD, PhD

Blood (2011) 118 (21): 2558.

https://doi.org/10.1182/blood.V118.21.2558.2558

Published: 2011

Journal Articles

The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2Rγc −/− Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/− Clofarabine Chemotherapy

Sylvia Chien, Xin Zhao, MD, Thalia Papayannopoulou, Frederick R. Appelbaum, MD, Pamela S. Becker, MD, PhD

Blood (2011) 118 (21): 1432.

https://doi.org/10.1182/blood.V118.21.1432.1432

Published: 2011

Journal Articles

Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine

Sylvia Chien, Xin Zhao, MD, John T. Patton, PhD, Theodore Smith, Arun Sarkar, PhD, John L. Magnani, Frederick R. Appelbaum, MD, Pamela S Becker, MD, PhD

Blood (2011) 118 (21): 579.

https://doi.org/10.1182/blood.V118.21.579.579

Published: 2011

NARROW

Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Precision Medicine Assays Detect Novel Targetable FLT3 Fusions Amenable to Therapeutic Intervention in a Patient with Refractory Acute Myeloid Leukemia

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage

Feasibility Trial of Individualized Therapy for Relapsed or Refractory Acute Myeloid Leukemia Based on a High Throughput in Vitro Drug Sensitivity Assay

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay

Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation

A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2Rgc −/− Mice Engrafted with Human AML

Characterization of Mesenchymal Stromal Cells (MSCs) Derived From Acute Myeloid Leukemia (AML) Bone Marrow

The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2Rγc −/− Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/− Clofarabine Chemotherapy

Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only